arrow
D

Daniil Stroyakovskiy

city clinical oncology hospital 62
H指数:48
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Final analysis of the FeDeriCa phase III study: long-term efficacy, safety and pharmacokinetics of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection, plus chemotherapy, in HER2-positive early breast cancer

FeDeriCa III期研究的最终分析:在HER2阳性早期乳腺癌患者中,曲妥珠单抗和帕妥珠单抗固定剂量联合皮下注射方案联合化疗的长期疗效、安全性和药代动力学

2026-07-310
OA
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

携带EGFR突变型晚期非小细胞肺癌患者使用amivantamab-lazertinib的总体生存率

2025-09-019
PRE
Corrigendum to “Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial” [Eur J Cancer. 227 (2025) 115674]

勘误:“低剂量抗CTLA-4(Nurulimab)联合抗PD-1(Prolgolimab)对比抗PD-1单药治疗晚期皮肤黑色素瘤的临床结局改善:OCTAVA III期试验结果”[Eur J Cancer. 227 (2025) 115674]

2025-08-300
PRE
Improved Clinical Outcomes with Low-Dose Anti–CTLA-4 (Nurulimab) Plus Anti–PD-1 (Prolgolimab) vs. Anti–PD-1 Monotherapy in Advanced Cutaneous Melanoma: Results from the Phase III OCTAVA Trial

低剂量抗–CTLA-4(Nurulimab)联合抗–PD-1(Prolgolimab)与抗–PD-1单药治疗在晚期皮肤黑色素瘤中的改善临床疗效:III期OCTAVA试验结果

2025-08-050
PRE
Summary of Research: Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

研究总结: 通过招募HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2025-03-010
OAAI
Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

Prolgolimab联合化疗作为一线治疗晚期非鳞非小细胞肺癌

2025-02-010
PRE
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

一项III期临床试验,比较在激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌患者中,辅助瑞博西尼联合内分泌疗法与单独内分泌疗法的效果:NATALEE试验的最终浸润性疾病无进展生存结果

2025-02-017
PRE
Real-world efficacy of lenvatinib and pembrolizumab as first-line therapy in patients with metastatic renal cell carcinoma with high burden disease

仑伐替尼和帕博利珠单抗在治疗高肿瘤负荷的转移性肾细胞癌患者中的一线治疗真实世界疗效

2024-12-010
PRE
Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2L early breast cancer (EBC)

亚洲和非亚洲患者(pts)在NATALEE试验中,接受ribociclib(RIB)联合非甾体类芳香化酶抑制剂(NSAI)治疗人表皮生长因子受体2低表达激素受体阳性早期乳腺癌(EBC)的分析

2024-12-010
PRE
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab联合Lazertinib治疗先前未经治疗的EGFR突变的晚期NSCLC

2024-10-2425
PRE
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

通过纳入HER2 IHC状态: DESTINY-PanTumor02的事后分析,曲妥珠单抗Deruxtecan在HER2-Expressing实体瘤中的疗效

2024-09-111
OAAI
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Amivantamab联合lazertinib与osimertinib治疗具有高危疾病生物标志物的一线EGFR突变晚期非小细胞肺癌: 来自MARIPOSA的二次分析

2024-09-015
OAAI
Anti-PD1+low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis

PD1抗体联合低剂量CTLA4抗体免疫疗法在III期可切除黑色素瘤患者中的病理缓解率:III期NEOMIMAJOR试验中期分析

2024-09-010
PRE
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer

阳光的通俗易懂的总结: 三氟尿苷/替匹拉西和贝伐单抗治疗难治性转移性结直肠癌

2024-07-020
OAAI
Ribociclib plus Endocrine Therapy in Early Breast Cancer
2024-03-2156
PRE
Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
2023-11-010
PRE
Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC)
2023-10-011
OAAI